Odonate Therapeutics Stock Forecast, Price & News

Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

Is Odonate Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Odonate Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ODT, but not buy additional shares or sell existing shares.
View analyst ratings for Odonate Therapeutics or view top-rated stocks.

How has Odonate Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ODT stock has decreased by 95.8% and is now trading at $1.09.
View which stocks have been most impacted by COVID-19.

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a decrease in short interest in December. As of December 31st, there was short interest totaling 379,600 shares, a decrease of 35.8% from the December 15th total of 591,500 shares. Based on an average daily volume of 841,500 shares, the short-interest ratio is currently 0.5 days. Currently, 1.2% of the shares of the company are short sold.
View Odonate Therapeutics' Short Interest.

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Odonate Therapeutics.

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics, Inc. (NASDAQ:ODT) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.33.
View Odonate Therapeutics' earnings history.

What price target have analysts set for ODT?

4 Wall Street analysts have issued 12-month price objectives for Odonate Therapeutics' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Odonate Therapeutics' stock price to reach $4.00 in the next year. This suggests a possible upside of 267.0% from the stock's current price.
View analysts' price targets for Odonate Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:

• Kevin C. Tang, Chairman & Chief Executive Officer
• Ryan Cole, Senior Vice President-Operations
• Michael S. Hearne, Chief Financial Officer
• Thomas Wei, Chief Scientific Officer
• Steven Pfeiffer, Senior Vice President-Technical Operations

Who are some of Odonate Therapeutics' key competitors?

Some companies that are related to Odonate Therapeutics include Frequency Therapeutics (FREQ), Anebulo Pharmaceuticals (ANEB), TFF Pharmaceuticals (TFFP), CorMedix (CRMD), PDS Biotechnology (PDSB), Humanigen (HGEN), Inozyme Pharma (INZY), Atossa Therapeutics (ATOS), UroGen Pharma (URGN), PLx Pharma (PLXP), Clene (CLNN), Spectrum Pharmaceuticals (SPPI), Larimar Therapeutics (LRMR), InflaRx (IFRX) and DURECT (DRRX).
View all of ODT's competitors.

What other stocks do shareholders of Odonate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (ATNX), BioCryst Pharmaceuticals (BCRX) and CRISPR Therapeutics (CRSP).

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $1.09.

How much money does Odonate Therapeutics make?

Odonate Therapeutics has a market capitalization of $41.95 million. The company earns $-126.35 million in net income (profit) each year or ($2.72) on an earnings per share basis.

How many employees does Odonate Therapeutics have?

Odonate Therapeutics employs 145 workers across the globe.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is www.odonate.com.

Where are Odonate Therapeutics' headquarters?

Odonate Therapeutics is headquartered at 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 731-8180 or via email at [email protected].